Glenmark Pharmaceuticals will host its Annual Investor Day 2026 on June 9, 2026, to discuss its financial and operational performance with analysts and institutional investors. The meeting is scheduled to take place in Mumbai and will be accessible through both physical and virtual modes. This event provides a platform for the company to present its strategic updates and business outlook.

The investor presentation will be made available on the website of the company and the stock exchanges prior to the event. The discussions during the meeting will be based on the financial and operational performance data published in the investor presentation and updates already submitted to the exchanges.

The schedule for the meeting is subject to change due to exigencies on the part of the investors or the company. Glenmark Pharmaceuticals Limited has informed the National Stock Exchange of India Limited and BSE Limited about the event in compliance with the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The company’s registered office is located at B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026. The compliance officer for the company can be reached at complianceofficer@glenmarkpharma.com .

Glenmark Pharmaceuticals Limited has appointed Ms. Rashmi Khandelwal as its new Company Secretary & Compliance Officer, effective May 30, 2026. The appointment follows the early retirement of Mr. Harish Kuber from the position, effective the close of business hours on May 29, 2026. The Board of Directors approved these changes during a meeting held on May 29, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The transition in the compliance office comes as Mr. Kuber stepped down after more than nine and a half years with the company. The Board accepted his resignation, noting that he is willing to continue for a few months to ensure a smooth transition. The company has disclosed the details of the cessation and the new appointment as required under SEBI regulations.

Ms. Khandelwal brings over 17 years of post-qualification experience in corporate governance, regulatory matters, and strategic transactions. She is a qualified Company Secretary and legal professional, having previously worked with entities such as Crompton Greaves Consumer Electricals Limited, ACC Limited, Yes Bank Limited, and Vaish Associates Advocates. Her expertise includes corporate restructuring, stakeholder management, and governance transitions, including the acquisition of ACC Limited and Ambuja Cements Limited by the Adani Group.

In a separate decision, the Board appointed Mr. Samir Kazi as a Senior Management Personnel of the company. He serves as the Executive Vice President & Head Legal, Compliance & IP. Mr. Kazi has more than two decades of experience in the pharmaceutical, corporate, and consulting sectors, having previously held leadership roles at Pfizer Limited and the Hinduja Group India Pvt Ltd.

Key Appointments

Cessation Details